Association of genetic variants in six candidate genes with valproic acid therapy optimization

Pharmacogenomics

Volumn 12, Issue 8, 2011, Pages 1107-1117

  Hung, Chin Chuan ^a,b   Ho, Jia Ling ^a   Chang, Wei Lun ^a   Tai, John Jen ^c   Hsieh, Tsung Jen ^c   Hsieh, Yow Wen ^a,b   Liou, Horng Huei ^d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

GRIN2B; pharmacogenomic; polymorphism; UGT1A6; UGT2B7; valproic acid

Indexed keywords

FATTY ACID BINDING PROTEIN 2; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; VALPROIC ACID;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; EPILEPSY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACOGENOMICS; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STEADY STATE; TEMPORAL LOBE EPILEPSY;

ADULT; ALLELES; ANTICONVULSANTS; DNA; EPILEPSY; EPILEPSY, GENERALIZED; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VALPROIC ACID;

EID: 80051748173     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.64     Document Type: Article

References (50)

1. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58, 31-59 (1999). (Pubitemid 29166878)
2. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51 (2006). (Pubitemid 43054973)
3. Ferraro TN, Buono RJ. The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav. 7, 18-36 (2005). (Pubitemid 40975276)
4. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16, 669-694 (2002). (Pubitemid 35176853)
5. Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem. Int. 37, 103-110 (2000). (Pubitemid 30254142)
6. Aksenova MG, Burd SG, Kachalin EY et al. An association between the FABP2 gene polymorphism and efficacy of valproates. Zh Nevrol. Psikhiatr. Im. S S Korsakova 107, 42-45 (2007).
7. Hsu KT, Storch J. Fatty acid transfer from liver and intestinal fatty acid-binding proteins to membranes occurs by different mechanisms. J. Biol. Chem. 271, 13317-13323 (1996). (Pubitemid 26185369)
8. Weiss EP, Brown MD, Shuldiner AR, Hagberg JM. Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects. Physiol. Genomics 10, 145-157 (2002). (Pubitemid 135707437)
9. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther. Drug Monit. 11, 127-133 (1989). (Pubitemid 19064835)
10. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol. Bull. 37(Suppl. 2), 25-42 (2003).
11. Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem. Pharmacol. 65, 1441-1449 (2003). (Pubitemid 36555832)
12. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab. Dispos. 26, 507-512 (1998). (Pubitemid 28498354)
13. Green MD, Tephly TR. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab. Dispos. 24, 356-363 (1996). (Pubitemid 26089830)
14. Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab. Dispos. 37, 229-236 (2009).
15. Saito K, Moriya H, Sawaguchi T et al. Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin. Biochem. 39, 303-308 (2006).
16. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 26, 73-77 (1998). (Pubitemid 28071328)
17. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 25, 1-4 (1997). (Pubitemid 27045126)
18. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J. Pharmacol. Exp. Ther. 264, 475-479 (1993). (Pubitemid 23309239)
19. Samokyszyn VM, Gall WE, Zawada G et al. 4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. J. Biol. Chem. 275, 6908-6914 (2000). (Pubitemid 30146232)
20. Hirota T, Ieiri I, Takane H et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab. Dispos. 31, 677-680 (2003). (Pubitemid 36444178)
21. Bhasker CR, McKinnon W, Stone A et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10, 679-685 (2000).
22. Girard H, Court MH, Bernard O et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14, 501-515 (2004). (Pubitemid 39100002)
23. Krishnaswamy S, Hao Q, Al-Rohaimi A et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther. 313, 1340-1346 (2005). (Pubitemid 40727040)
24. Krishnaswamy S, Duan SX, Von Moltke LL, Greenblatt DJ, Court MH. Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab. Dispos. 31, 133-139 (2003). (Pubitemid 36735267)
25. Girard H, Villeneuve L, Court MH et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab. Dispos. 34, 1220-1228 (2006).
26. Sun YP, Tan L, Wang Y, Song JH. [Effect of UGT1A6 genetic polymorphisms on the metabolism of sodium valproate]. Zhonghua Yi Xue Za Zhi 87, 2033-2035 (2007). (Pubitemid 350019958)
27. Tate SK, Depondt C, Sisodiya SM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102, 5507-5512 (2005). (Pubitemid 40530288)
28. Tate SK, Singh R, Hung CC et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 16, 721-726 (2006). (Pubitemid 44454866)
29. Heinzen EL, Yoon W, Tate SK et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am. J. Hum. Genet. 80, 876-883 (2007). (Pubitemid 46668456)
30. Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur.J. Neurol. (2011).
31. No authors listed. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30, 389-399 (1989).
32. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51, 1069-1077 (2010).
33. Jiang H, Jia J. Association between NR2B subunit gene (GRIN2B) promoter polymorphisms and sporadic Alzheimer's disease in the North Chinese population. Neurosci. Lett. 450, 356-360 (2009).
34. Makmor-Bakry M, Sills GJ, Hitiris N, Butler E, Wilson EA, Brodie MJ. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clin. Neuropharmacol. 32, 205-212 (2009).
35. Nagar S, Zalatoris JJ, Blanchard RL. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14, 487-499 (2004). (Pubitemid 39100001)
36. Miyatake R, Furukawa A, Suwaki H. Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia. Mol. Psychiatry 7, 1101-1106 (2002). (Pubitemid 36044269)
37. van Schaik RH, van Agteren M, de Fijter JW et al. UGT1A9-275T
38. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther. 320, 331-343 (2007). (Pubitemid 46025748)
39. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol. 12, 921-927 (1995).
40. Lewontin RC. The interaction of selection and linkage. II. Optimum models. Genetics 50, 757-782 (1964).
41. Lewontin RC. The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 49, 49-67 (1964).
42. Kelly PJ, Stallard N, Whittaker JC. Statistical design and analysis of pharmacogenetic trials. Stat. Med. 24, 1495-1508 (2005). (Pubitemid 40716349)
43. Wang Y, Gao L, Liu YP, Huang NN, Xu SJ, Ma DJ. [Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan]. Zhongguo Dang Dai Er Ke Za Zhi 12, 429-432 (2010).
44. Chung JY, Cho JY, Yu KS et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin. Pharmacol. Ther. 83, 595-600 (2008).
45. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132, 272-281 (2007). (Pubitemid 46108755)
46. Holthe M, Rakvag TN, Klepstad P et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 3, 17-26 (2003). (Pubitemid 36432463)
47. Levesque E, Delage R, Benoit-Biancamano MO et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin. Pharmacol. Ther. 81, 392-400 (2007). (Pubitemid 46364482)
48. Ross JR, Rutter D, Welsh K et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 5, 324-336 (2005). (Pubitemid 41486231)
49. Blanca Sanchez M, Herranz JL, Leno C et al. UGT2B7-161C
50. Garcia-Saiz M, Lopez-Gil A, Alfonso I, Boada JN, Armijo JA. Factors influencing cyclosporine blood concentration-dose ratio. Ann. Pharmacother. 36, 193-199 (2002). (Pubitemid 34126806)